These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 27595539)
1. The solithromycin journey-It is all in the chemistry. Fernandes P; Martens E; Bertrand D; Pereira D Bioorg Med Chem; 2016 Dec; 24(24):6420-6428. PubMed ID: 27595539 [TBL] [Abstract][Full Text] [Related]
2. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. Zhanel GG; Hartel E; Adam H; Zelenitsky S; Zhanel MA; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty AJ; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995 [TBL] [Abstract][Full Text] [Related]
3. Nature nurtures the design of new semi-synthetic macrolide antibiotics. Fernandes P; Martens E; Pereira D J Antibiot (Tokyo); 2017 May; 70(5):527-533. PubMed ID: 27899792 [TBL] [Abstract][Full Text] [Related]
4. Solithromycin (CEM-101): A New Fluoroketolide Antibiotic and Its Role in the Treatment of Gonorrhea. Mancuso AM; Gandhi MA; Slish J J Pharm Pract; 2018 Apr; 31(2):195-201. PubMed ID: 28490220 [TBL] [Abstract][Full Text] [Related]
5. Surveillance of the activity of solithromycin (CEM-101) against bacteria from respiratory tract infections. Hawser S; Morrissey I; Lemos B; Keedy K; Fernandes P Int J Antimicrob Agents; 2017 Jul; 50(1):17-22. PubMed ID: 28483717 [TBL] [Abstract][Full Text] [Related]
6. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia. File TM; Rewerska B; Vucinic-Mihailovic V; Gonong JRV; Das AF; Keedy K; Taylor D; Sheets A; Fernandes P; Oldach D; Jamieson BD Clin Infect Dis; 2016 Oct; 63(8):1007-1016. PubMed ID: 27448679 [TBL] [Abstract][Full Text] [Related]
7. The role of solithromycin in the management of bacterial community-acquired pneumonia. Van Bambeke F; Tulkens PM Expert Rev Anti Infect Ther; 2016; 14(3):311-24. PubMed ID: 26848612 [TBL] [Abstract][Full Text] [Related]
8. Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy. Donald BJ; Surani S; Deol HS; Mbadugha UJ; Udeani G Drug Des Devel Ther; 2017; 11():3559-3566. PubMed ID: 29263651 [TBL] [Abstract][Full Text] [Related]
9. In Vitro Activity of Solithromycin against Bordetella pertussis, an Emerging Respiratory Pathogen. Hardy DJ; Vicino D; Fernandes P Antimicrob Agents Chemother; 2016 Dec; 60(12):7043-7045. PubMed ID: 27620481 [TBL] [Abstract][Full Text] [Related]
10. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition. Kobayashi Y; Wada H; Rossios C; Takagi D; Higaki M; Mikura S; Goto H; Barnes PJ; Ito K J Pharmacol Exp Ther; 2013 Apr; 345(1):76-84. PubMed ID: 23359665 [TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012. Farrell DJ; Mendes RE; Jones RN Antimicrob Agents Chemother; 2015 Apr; 59(4):2432-4. PubMed ID: 25605359 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci. Putnam SD; Sader HS; Farrell DJ; Biedenbach DJ; Castanheira M Int J Antimicrob Agents; 2011 Jan; 37(1):39-45. PubMed ID: 21075602 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. Farrell DJ; Sader HS; Castanheira M; Biedenbach DJ; Rhomberg PR; Jones RN Int J Antimicrob Agents; 2010 Jun; 35(6):537-43. PubMed ID: 20211548 [TBL] [Abstract][Full Text] [Related]
15. Overcoming the Challenges of Low Drug Solubility in the Intravenous Formulation of Solithromycin. Evans D; Yalkowsky S; Wu S; Pereira D; Fernandes P J Pharm Sci; 2018 Jan; 107(1):412-418. PubMed ID: 29107789 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of solithromycin and its metabolites, CEM-214 and N-acetyl-CEM-101, against 100 clinical Ureaplasma spp. isolates compared with azithromycin. Furfaro LL; Spiller OB; Keelan JA; Payne MS Int J Antimicrob Agents; 2015 Sep; 46(3):319-24. PubMed ID: 26141231 [TBL] [Abstract][Full Text] [Related]
17. Differentiating the Pharmacodynamics and Toxicology of Macrolide and Ketolide Antibiotics. Fernandes P; Pereira D; Watkins PB; Bertrand D J Med Chem; 2020 Jun; 63(12):6462-6473. PubMed ID: 31644280 [TBL] [Abstract][Full Text] [Related]
18. Telithromycin: the first of the ketolides. Shain CS; Amsden GW Ann Pharmacother; 2002 Mar; 36(3):452-64. PubMed ID: 11895060 [TBL] [Abstract][Full Text] [Related]
19. Alternative approaches utilizing click chemistry to develop next-generation analogs of solithromycin. Daher SS; Lee M; Jin X; Teijaro CN; Barnett PR; Freundlich JS; Andrade RB Eur J Med Chem; 2022 Apr; 233():114213. PubMed ID: 35240514 [TBL] [Abstract][Full Text] [Related]
20. Synthesis, Biological Evaluation, and Computational Analysis of Biaryl Side-Chain Analogs of Solithromycin. Daher SS; Lee M; Jin X; Teijaro CN; Wheeler SE; Jacobson MA; Buttaro B; Andrade RB ChemMedChem; 2021 Nov; 16(21):3368-3373. PubMed ID: 34355515 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]